SABS
SAB Biotherapeutics Inc

1,695
Mkt Cap
$195.41M
Volume
402,362.00
52W High
$6.60
52W Low
$1.00
PE Ratio
-1.33
SABS Fundamentals
Price
$4.10
Prev Close
$4.13
Open
$4.08
50D MA
$3.97
Beta
0.74
Avg. Volume
461,257.50
EPS (Annual)
-$3.68
P/B
1.18
Rev/Employee
$20,990.63
$19.05
Loading...
Loading...
News
all
press releases
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf
SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer's 36th Annual Healthcare Life Sciences Conference to outline its strategy in type 1 diabetes (T1D), emphasizing development of a...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Analysts
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. One...
MarketBeat·13d ago
News Placeholder
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 24.7%
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling...
MarketBeat·14d ago
News Placeholder
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026
SAB Biotherapeutics (NASDAQ:SABS) used a presentation at Guggenheim's Emerging Outlook Biotech Summit 2026 to outline its strategy in type 1 diabetes (T1D), focusing on a pivotal Phase 2b program for...
MarketBeat·15d ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 6.6% - Here's What Happened
SAB Biotherapeutics (NASDAQ:SABS) Stock Price Down 6.6% - Here's Why...
MarketBeat·16d ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat.com reports. One...
MarketBeat·1mo ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Increase in Short Interest
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 901,471 shares, a...
MarketBeat·2mo ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are currently covering the firm...
MarketBeat·2mo ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company...
MarketBeat·3mo ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen raised SAB Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·3mo ago
<
1
2
...
>

Latest SABS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.